Dual-Functional PLGA Nanoparticles Co-Loaded with Indocyanine Green and Resiquimod for Prostate Cancer Treatment by Lin, Wenfeng et al.
O R I G I N A L  R E S E A R C H
Dual-Functional PLGA Nanoparticles Co-Loaded 
with Indocyanine Green and Resiquimod for 
Prostate Cancer Treatment
This article was published in the following Dove Press journal: 
International Journal of Nanomedicine
Wenfeng Lin1,* 










1Department of Urology, Okayama 
University Graduate School of Medicine, 
Dentistry and Pharmaceutical Sciences, 
Okayama, Japan; 2Department of 
Urology, Zhujiang Hospital, Southern 
Medical University, Guangzhou, People’s 
Republic of China; 3Department of 
Urology, Sir Run Run Shaw Hospital, 
Zhejiang University School of Medicine, 
Hangzhou, People’s Republic of China; 
4Center for Innovative Clinical Medicine, 
Okayama University Hospital, Okayama, 
Japan; 5Center for Scientific Research, 
Yunnan University of Chinese Traditional 
Medicine, Kunming, People’s Republic of 
China; 6Okayama Medical Innovation 
Center, Okayama University, Okayama, 
Japan  
*These authors contributed equally to 
this work  
Purpose: With the advance of screening techniques, there is a growing number of low-risk 
or intermediate-risk prostate cancer (PCa) cases, remaining a serious threat to men’s health. 
To obtain better efficacy, a growing interest has been attracted to develop such emerging 
treatments as immunotherapy and focal therapy. However, few studies offer guidance on 
whether and how to combine these modalities against PCa. This study was designed to 
develop dual-functional nanoparticles (NPs) which combined photothermal therapy (PTT) 
with immunotherapy and determine the anti-tumor efficacy for PCa treatment.
Methods: By a double emulsion technique, the drug nanocarrier, poly(lactic-co-glycolic 
acid) or PLGA, was applied for co-loading of a fluorescent dye, indocyanine green (ICG) and 
a toll-like receptor 7/8 (TLR7/8) agonist resiquimod (R848) to synthesize PLGA-ICG-R848 
NPs. Next, we determined their characteristic features and evaluated whether they inhibited 
the cell viability in multiple PCa cell lines. After treatment with PLGA-ICG-R848, the 
maturation markers of bone marrow-derived dendritic cells (BMDCs) were detected by 
flow cytometry. By establishing a subcutaneous xenograft model of mouse PCa, we explored 
both the anti-tumor effect and immune response following the NPs-based laser ablation.
Results: With a mean diameter of 157.7 nm, PLGA-ICG-R848 exhibited no cytotoxic effect 
in PCa cells, but they significantly decreased RM9 cell viability to (3.9±1.0)% after laser 
irradiation. Moreover, PLGA-ICG-R848 promoted BMDCs maturation with the significantly 
elevated proportions of CD11c+CD86+ and CD11c+CD80+ cells. Following PLGA-ICG- 
R848-based laser ablation in vivo, the decreased bioluminescent signals indicated 
a significant inhibition of PCa growth, while the ratio of splenic natural killer (NK) cells 
in PLGA-ICG-R848 was (3.96±1.88)% compared with (0.99±0.10)% in PBS group, reveal-
ing the enhanced immune response against PCa.
Conclusion: The dual-functional PLGA-ICG-R848 NPs under laser irradiation exhibit the 
anti-tumor efficacy for PCa treatment by combining PTT with immunotherapy.
Keywords: prostate cancer, PLGA, indocyanine green, resiquimod, photothermal therapy, 
immunotherapy
Introduction
Prostate cancer (PCa) poses a serious threat to men’s health with the second highest 
incidence of all malignant tumors in men worldwide.1 According to the Cancer 
Statistics 2020, it has been estimated that there would be 191,930 new cases of PCa, 
accounting for 21% of all male malignancies, and that 33,330 patients would die of 
this disease in the United States.2 Therapeutic strategies for PCa consist of 
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surveillance, localized therapy and systemic therapy. 
Localized therapy includes surgery, radiation therapy and 
focal therapy while systemic therapy includes hormonal 
therapy, chemotherapy and immunotherapy.3,4 Generally, 
treatment options depend partly on whether PCa is loca-
lized, high-risk, advanced or recurrent. Due to the limited 
efficacy and side effects of monotherapy, effective combi-
nation therapies or novel treatment regimens still need to 
be developed to obtain better efficacy outcomes.5 
Recently, a growing interest has been attracted to such 
novel treatments as immunotherapy6 and PTT therapy.7 
However, few available studies can offer guidance to 
whether and how to combine these modalities, and their 
synergistic applications may give another perspective in 
the treatment of PCa.
Accumulating evidence suggests that human PCa does 
not respond well to mono-immunotherapy due to the low 
infiltration of effective immune cell types, which is also 
known as immunologically “cold”.8 Cancer vaccines are 
considered as promising strategies to modify the tumor 
microenvironment (TME) from “cold” to “hot” type.9 
Relative to conventional cancer vaccines, in situ cancer 
vaccines and effective adjuvants recently show great 
potential to overcome the limitations of poor immunogeni-
city, high cost and safety concerns.10 In situ vaccination 
aims to produce tumor-associated antigens (TAAs) at the 
tumor site without prior identification and isolation, which 
will further trigger a TAA-specific adaptive immune 
response.11 The application of immune adjuvants can 
effectively improve the immunogenicity of vaccines and 
enhance the specific immune response. Based on small- 
molecule agonists at toll-like receptor 7/8 (TLR7/8), 
a growing number of clinical trials have been conducted 
to assess the anti-tumor immunity in multiple cancers.12 
As a TLR7/8 agonist approved by Food and Drug 
Administration (FDA), resiquimod (R848) may be an 
immune adjuvant or a single immunomodulatory drug 
with important application prospects in cancer treatment, 
but very few studies have been conducted on the potential 
impacts of R848 used to treat PCa. It must be noted that 
free R848 rapidly induces a systemic production of inflam-
matory cytokines, leading to potential adverse events and 
safety risks,13 which can be reduced by its encapsulation 
in NPs.
The emerging treatment modality, focal therapy, 
mainly consists of cryotherapy, high-intensity focused 
ultrasound (HIFU), laser ablation, photodynamic therapy 
(PDT), irreversible electroporation, radiofrequency 
ablation and focal brachytherapy.14 With Prostate 
Specific Antigen (PSA) screening being widely used, an 
increasing number of PCa cases are diagnosed as low-risk 
or intermediate-risk.15 Therefore, focal therapy will play 
a more critical role due to both the ablation of prostate 
cancer lesions similar to surgical removal and the protec-
tive effects of urinary and sexual functions.16 However, 
further clinical and basic research data are still needed to 
confirm its therapeutic effects. As an amphiphilic near- 
infrared (NIR) fluorescent dye, indocyanine green (ICG) 
can not only efficiently convert the absorbed light energy 
to heat for photothermal therapy (PTT) but also induce 
reactive oxygen species (ROS) production for PDT,17 
which may serve as a promising anticancer reagent by 
laser ablation. However, it should be noted that both the 
instability of ICG in water, light, heat and the rapid clear-
ance in vivo pose serious obstacles to its practical use. 
Increasing evidence suggests that ICG encapsulated in 
nanoparticles (NPs) can overcome the above deficiencies 
and exhibit the enhanced effects of cancer therapy.18
As one of the most widely applied drug nanocarriers, 
poly(lactic-co-glycolic acid) or PLGA exhibits the favor-
able properties such as sustained drug release, biocompat-
ibility, non-toxicity, non-immunogenicity and 
biodegradability.19,20 The present research aimed to 
develop a dual-functional PLGA NPs co-loaded with 
ICG and R848 (PLGA-ICG-R848 NPs), and then deter-
mined their in vitro and in vivo anticancer efficacy for PCa 
treatment when irradiated with 808 nm laser. Our findings 
could give another perspective in the development of 




Poly(lactic-co-glycolic acid) (PLGA, #719889), resiqui-
mod (R848, #SML0196) and indocyanine green (ICG, 
#I2633) were purchased from Sigma-Aldrich. 
Dichloromethane (DCM, #270997), dimethyl sulfoxide 
(DMSO, #472301) and polyvinyl alcohol (PVA, 
#363170) were also provided by Sigma-Aldrich. 
Recombinant mouse GM-CSF (BioLegend, #576304), 
recombinant mouse IL-4 (BioLegend, #574304), lipopoly-
saccharides (LPS, Sigma-Aldrich, L4391), 1X RBC Lysis 
Buffer (Invitrogen, #00-4333) and 100-mm ultra-low 
attachment culture dish (Corning®, #3262) were obtained 
for BMDCs culture.
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Cell Lines and Cell Culture
The human prostate cancer cell lines PC-3, LNCaP and 
DU-145 were purchased from American Type Culture 
Collection (ATCC). The mouse prostate cancer cell line 
RM9 was a gift from Professor T.C. Thompson of 
University of Texas, USA. RM9 and DU-145 cells were 
cultured in Dulbecco’s modified eagle medium (DMEM; 
Gibco, Invitrogen, USA) supplemented with 10% fetal 
bovine serum (FBS; Gibco, Invitrogen, USA), 1% penicil-
lin-streptomycin (Gibco, Invitrogen, USA), and main-
tained at 37°C in a humidified atmosphere containing 5% 
CO2. PC-3 and LNCaP cells were cultured in the same 
environment, but in F-12 and RMPI-1640 media, respec-
tively, containing 10% FBS and 1% penicillin- 
streptomycin.
Preparation of PLGA-ICG-R848 NPs
PLGA-ICG-R848 was synthesized using a double emul-
sion/solvent evaporation technique.21 Briefly, 60 mg 
PLGA was co-dissolved in 2 mL DCM with 0.8 mg 
R848. Then, 0.2 mL of 3 mg/mL ICG solution was 
added to the mixture above, which was emulsified for 2 
min using ultrasonicator (Bioruptor UCD-250, Diagenode, 
Belgium). The primary emulsion was next ultrasonicated 
with 5 mL of 2.5% (w/v) PVA aqueous solution for 6 min 
to produce the w/o/w double emulsion. Transferred the w/ 
o/w emulsion to 5 mL of 0.25% (w/v) PVA aqueous 
solution and facilitated organic solvent evaporation under 
magnetic stirring for 4 h. The prepared PLGA-ICG-R848 
NPs were collected by centrifugation at 23,000 g for 20 
min, and washed twice with Milli-Q water. Finally, the 
freeze-dried powder of PLGA-ICG-R848 NPs was 
obtained after lyophilized for 24 h and stored at 4°C in 
the dark before use.
Characterization of PLGA-ICG-R848 NPs
The PLGA-ICG-R848 NPs were firstly dispersed in 
Milli-Q water and then presented to a dynamic light 
scattering (DLS) device named Zetasizer Nano ZSP 
(Malvern Panalytical, UK) for the determination of their 
particle sizes, polydispersity index (PDI) and zeta poten-
tial. The morphology and surface structure of NPs were 
characterized by scanning electron microscope (SEM; 
S-4800, Hitachi, Japan). The UV-VIS-NIR absorption 
spectra of free ICG, PLGA-ICG and PLGA-ICG-R848 
was confirmed by a microvolume spectrophotometer 
(DeNovix Inc., DS-11, USA). The FlexStation® 3 Multi- 
Mode Microplate Reader (Molecular Devices, USA) was 
used to measure the concentration of ICG with absor-
bance at 780 nm wavelength. High performance liquid 
chromatography (HPLC, LC-20AT, Shimadzu, Japan) 
coupled with an ultraviolet-visible detector (SPD-20A, 
Shimadzu, Japan), together with XTerra RP18 column 
(3.0 mm × 150 mm, 5.0 µm, Waters, USA) were applied 
to detect the concentration of R848 at 250 nm 
(Supplementary Figure 1A). HPLC analysis was per-
formed using mobile phase A (0.1% trifluoroacetic acid 
in acetonitrile) and mobile phase B (0.1% trifluoroacetic 
acid in water). The standard curve and linear regression 
equation of R848 are shown in Supplementary Figure 1B 
and C. For ICG measurement, we firstly collected the 
supernatant after centrifugation, and determined the con-
centration of free ICG in supernatant. Then, we calcu-
lated the weight of entrapped ICG by subtracting the 
weight of free ICG in supernatant from overall feeding 
weight. Encapsulation efficiency (EE%) and loading 
capacity (LC%) were calculated using the following 
formulation:
EE% ¼
Weight of entrapped drug
Over all feeding weight
� 100%
LC% ¼




RM9 cells were seeded on the coverslips in 24-well plates 
at a density of 3 × 104 cells per well and allowed to adhere 
overnight. Then the cells were treated for 2 h or 12 h with 
PLGA, PLGA-ICG, PLGA-R848 and PLGA-ICG-R848 at 
the same concentration of ICG (40 μM) or R848 (6.6 μg/ 
mL) in the absence of serum. The treated cells were fixed 
for 15 min in 4% formaldehyde at room temperature and 
rinsed three times with PBS for 5 min each. The intracel-
lular distribution of ICG was observed at different time 
points using an ICG filter equipped fluorescence micro-
scope (BZ-X700, Keyence, Japan). The software of Image 
J was used to quantify the mean fluorescence intensity 
(MFI) of ICG fluorescence from ten random fields of view.
Cell Viability Assay
Cells were seeded in 24-well plates and allowed to adhere 
for 24 h. After replacing with serum-free media, the cells 
were maintained overnight. For cytotoxicity test, RM9 
cells were incubated with PLGA-ICG-R848 with different 
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concentrations of ICG for 4 h and irradiated without or 
with 808 nm laser (1W/cm2) for 10 min. After 24 h, the 
cell viability was detected using cell proliferation kit 
(Roche, Germany). For cell proliferation assay, RM9, 
PC-3, LNCaP and DU-145 cells were firstly treated for 4 
h with PBS, PLGA, PLGA-R848, PLGA-ICG and PLGA- 
ICG-R848, containing the same concentration of ICG or 
R848 and next irradiated without or with 808nm laser 
(1W/cm2) for 10 min. After 24 h, the cell viability was 
detected using cell proliferation kit (Roche, Germany).
Generation and Maturation of BMDCs
Immature BMDCs were generated according to a standard 
protocol (BMDC isolation protocol, Abcam, USA). Bone 
marrow cells were isolated from the femurs and tibias of 
C57BL/6 mice (male, 8–10 weeks old) on day 0. After 
filtration on a 40 μm cell strainer and red blood cell lysis, 
bone marrow cells were then seeded in 100-mm Ultra-Low 
Attachment Culture Dish containing 10 mL RPMI-1640 
medium supplemented with 10% FBS, 20 ng/mL GM-CSF 
and 10 ng/mL IL-4. The cells were cultured at 37°C in an 
incubator containing 5% CO2. On day 3, an additional 
10 mL of RPMI-1640 medium was added, and then half 
of the culture medium was changed on day 6. During 
cultivation, the same concentrations of GM-CSF and IL- 
4 were maintained as above.
On day 8, both the semi-suspended cells and loosely 
attached cells were gently collected and plated into 6-well 
plates. The cells were treated for 48h with (1) PBS, (2) 
PLGA, (3) PLGA-ICG, (4) PLGA-R848, (5) PLGA-ICG- 
R848, (6) R848 (5 μg/mL) and (7) LPS (0.1 μg/mL). LPS 
at 100ng/mL was used as the positive control.
On day 10, BMDCs were stained with anti-CD11c PE 
(BD Pharmingen™, #557401), anti-CD86 FITC (BD 
Pharmingen™, #553691) and anti-CD80 APC (BD 
Pharmingen™, #560016), and then analysed by flow cyto-
metry (Miltenyi Biotec, Germany).
PLGA-ICG-R848 Treatment for 
Subcutaneous Xenograft Model of 
RM9-Luc PCa Cells
Six-week-old male C57BL/6J mice were provided by 
Japan SLC, Inc. (Shizuoka, Japan) and were acclimated 
for 2 weeks. Animal experimental protocols were 
approved by the Ethics Review Committee for Animal 
Experimentation of Okayama University (No. OKU- 
2018003). The welfare and treatment of the laboratory 
animals followed the Guideline of Animal Experiment in 
Okayama University. The use of RM9 cell line was 
approved by the Okayama University Animal Research 
Committee. RM9 cells were infected with plasmids con-
taining luciferase and named RM9-Luc cells, which was 
also reported in our previous studies.22,23
For the tumor inoculation, RM9-Luc cells (2×105) 
resuspended in 100 µL PBS were subcutaneously inocu-
lated into the left flank of each mouse. Ten days later, the 
tumor volume reached approximately 150 mm3 and the 
mice were randomized into the following groups: (1) PBS, 
(2) PBS+laser, (3)PLGA-ICG+laser, (4)PLGA-ICG-R848 
+laser. Nanoparticle suspension in 100 μL (1.6 mg/kg 
ICG, 0.33 mg/kg R848 per mouse) was injected intratu-
morally. According to the results of cellular uptake experi-
ment and cell viability assay, 808nm laser (0.8 W/cm2) 
was used to irradiate the tumor for 10 min after 4 
h injection. During laser irradiation, the subcutaneous 
temperature was monitored at 2 min, 4 min, 6 min, 8 
min and 10 min by FLIR thermal imager (FLIR Systems 
Inc., USA). The IVIS-200 Imaging System (Xenogen, 
Alameda, CA, USA) was applied to acquire biolumines-
cence images and analyze tumor growth.
Two weeks after treatment, spleens were collected to 
make single cell splenocyte suspensions. Splenocytes were 
stained with anti-CD3 PE (BD Pharmingen™, #553064), 
anti-NK1.1 FITC (BD Pharmingen™, #553164). The 
MACSQuant Analyzer 10 (Miltenyi Biotec, Germany) 
was used to detect and analyze the proportion of natural 
killer (NK) cells.
Statistical Analysis
Data are presented as mean ± standard error (mean ± SD) 
unless otherwise indicated. Statistical analyses were per-
formed using GraphPad Prism 8.3. Statistical significance 
was determined by analysis of variance (ANOVA). 
Differences were regarded as significant at P < 0.05.
Results
Preparation and Characterization of 
PLGA-ICG-R848 NPs
PLGA-ICG-R848 NPs prepared from a double emulsion 
assay were characterized by DLS device and SEM. 
Consistent with the nanoparticle size and shape characteriza-
tion observed by SEM analysis, a mean diameter of 157.7 nm 
was determined by DLS device (Figure 1A and B). DLS 
device also revealed that the PDI of PLGA-ICG-R848 was 
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0.071 and the zeta potential was −35.1 mV, indicating a good 
stability of NPs in water solution. Then the prepared solution 
was observed under IVIS-200 Imaging System equipped 
with ICG filter. Fluorescence could be detected in the solu-
tion containing ICG ingredient such as free ICG, PLGA-ICG 
and PLGA-ICG-R848, but was not observed in PLGA, 
PLGA-R848, PBS solution (Figure 1C). The characteristic 
absorption peaks of ICG and R848 were identified by DS-11 
microvolume spectrophotometer, demonstrating the success-
ful encapsulation of ICG and R848 in the PLGA core (Figure 
1D). ICG concentration was calculated by subtracting the 
residual weight from feeding weight. The encapsulation effi-
ciency and loading capacity were (65.61±2.09)% and (0.82 
±0.03)%, respectively, for ICG, while they were (8.363 
±0.325)% and (0.131±0.004)%, respectively, for R848.
Successful Cellular Uptake of PLGA-ICG- 
R848 NPs and They Inhibit the Cell 
Viability of PCa Cells After Laser 
Irradiation
To confirm the successful cellular uptake of NPs, RM9 
cells were treated with PLGA, PLGA-ICG, PLGA-R848 
and PLGA-ICG-R848 for 2 h or 12 h. After incubation 
with NPs containing ICG ingredient for 2 h, fluorescence 
of ICG appeared in RM9 cells, and stronger fluorescence 
was observed when the incubation time was longer. But 
the groups without ICG ingredient presented no ICG fluor-
escence (Figure 2A). As shown in Figure 2B, there was no 
significant difference in the MFI of ICG fluorescence 
between PLGA-R848 (2h) and PLGA-ICG-R848 (2h), or 
between PLGA-R848 (12h) and PLGA-ICG-R848 (12h).
For cytotoxicity test, RM9 cells were incubated with 
PLGA-ICG-R848 with different concentrations of ICG. 
The cell viability exhibited no significant difference 
regardless of different ICG concentrations in the group 
of PLGA-ICG-R848. But after exposing the treated RM9 
cells to 808 nm laser irradiation, the viability rate sig-
nificantly decreased in a concentration-dependent manner 
(Figure 2C). For cell proliferation assay, RM9 cells and 
human prostate cancer cell lines including PC-3, LNCaP 
and DU-145 were treated for 4 h with PBS, PLGA, 
PLGA-R848, PLGA-ICG and PLGA-ICG-R848 and 
next irradiated without or with laser. The cell viability 
of PLGA-ICG+laser and PLGA-ICG-R848+laser was 
significantly inhibited after 24 h culture. But no signifi-
cant inhibition was found in groups of PBS, PBS+laser, 
PLGA+laser and PLGA-R848+laser (Figure 2D).
PLGA-ICG-R848 NPs Promote BMDCs 
Maturation
On day 10 when BMDCs were stimulated for 48 h, more 
cells with enlarged volume and dendritic structure were 
observed by microscopy in groups of PLGA-R848, PLGA- 
ICG-R848, R848 (5 μg/mL) and LPS (0.1 μg/mL) than in 
other groups. Both the non-adherent and loosely adherent 
cells were gently collected, and flow cytometry was per-
formed to detect CD11c marker (a specific surface marker 
of murine dendritic cells), CD86 and CD80 markers (cost-
imulatory factors to provide the second signal of T cell 
activation). The representative results of CD11c+CD86+ 
cells and CD11c+CD80+ cells are shown in Figure 3A and 
B, respectively. The ratios of CD11c+ cells were more 
than 91% in all groups and were not significantly different 
between any two groups, indicating a relatively high purity 
of BMDCs.
The ratios of CD11c+CD86+ cells were (38.54 
±1.30)%, (41.41±6.92)%, (44.04±3.24)%, (62.84 
±1.76)%, (63.70±2.08)%, (65.71±9.14)% and (90.96 
±4.31)%, in the groups of Control, PLGA, PLGA-ICG, 
PLGA-R848, PLGA-ICG-R848, R848 (5μg/mL) and 
LPS (0.1 μg/mL), respectively (Figure 3C). Similar to 
the proportional change of CD11c+CD86+ cells, the 
ratios of CD11c+CD80+ cells were (40.43±1.22)%, 
(47.16±6.66)%, (44.62±6.23)%, (68.56±1.86)%, (70.61 
±3.70)%, (71.54±3.77)% and (91.59±0.57)%, in the 
groups of Control, PLGA, PLGA-ICG, PLGA-R848, 
PLGA-ICG-R848, R848 (5μg/mL) and LPS (0.1 μg/ 
mL), respectively (Figure 3C). The percentage of 
CD11c+CD86+ cells in any group of PLGA-R848, 
PLGA-ICG-R848 and R848 (5μg/mL) was significantly 
higher than that in any group of Control, PLGA and 
PLGA-ICG, and it was the same as CD11c+CD80+ cells.
PLGA-ICG-R848 NPs Plus NIR Laser 
Exhibit the Anti-Tumor Effect on PCa 
Mouse Model
To assess the anti-tumor effect of PLGA-ICG-R848 NPs, 
we established the RM9-Luc subcutaneous tumor xeno-
graft model. During laser irradiation (0.8 W/cm2, 10 min), 
the subcutaneous temperatures at 2, 4, 6, 8 and 10 min 
were controlled around 50°C in the groups of PLGA-ICG 
+laser, PLGA-ICG-R848+laser and below 40°C in the 
group of PBS+laser (Figure 4A and B).
Two weeks after treatment, in vivo bioluminescence 
imaging was performed to monitor tumor growth and 
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bioluminescent images were quantified using Living 
Image 3.2 software. The luminescent signals in the groups 
of (3)PLGA-ICG+laser and (4)PLGA-ICG-R848+laser 
were significantly lower than those in the groups of (1) 
PBS and (2) PBS+laser (Figure 4C and D).
To evaluate the immune response after PLGA-ICG- 
R848 treatment, spleens were collected for flow cytometry. 
In splenocytes, the ratio of CD3-NK1.1+ cells in (4) 
PLGA-ICG-R848+laser was (3.96±1.88)%, which was 
significantly higher than (0.99±0.10)% in (1) PBS 
(Figure 4E and F).
Discussion
To obtain better efficacy against PCa, a growing interest has 
been attracted to develop multi-functional nanoparticles, such 
as chemotherapy, gene therapy and immunotherapy.24–26 In 
this study, we successfully synthesized dual-functional PLGA- 
ICG-R848 NPs with three clinically proven ingredients 
(PLGA, ICG and R848), and demonstrated the in vitro and 
in vivo anticancer efficacy of PLGA-ICG-R848 NPs when 
irradiated with 808 nm NIR laser (Figure 5A). The data of 
particle size, zeta potential and PDI revealed a good stability of 
PLGA-ICG-R848 NPs. We measured the mean particle size of 
157.7 nm (>100 nm). According to the related studies,27,28 the 
mean particle size and our results of cellular uptake experi-
ment, PLGA-ICG-R848 NPs may be internalized mainly by 
clathrin-mediated endocytic pathway, and the results of cell 
viability assay indicate that PLGA-ICG-R848 NPs without 
laser irradiation had a low toxicity to prostate cancer cells. 
The cellular uptake of NPs containing ICG was demonstrated 
by our observation of stronger ICG fluorescence in RM9 cells 
with longer incubation time.
Figure 1 Preparation and characterization of PLGA-ICG-R848 NPs. (A) The mean diameter of PLGA-ICG-R848 NPs was determined by DLS device. (B) SEM analysis was 
applied to identify the nanoparticle size and shape characterization. Scale bar = 100nm. (C) Under IVIS-200 Imaging System, ICG fluorescence could be detected in groups of 
free ICG, PLGA-ICG and PLGA-ICG-R848, but was not observed in PLGA, PLGA-R848 and PBS. (D) The characteristic absorption peaks of ICG and R848 were identified 
by DS-11 microvolume spectrophotometer, demonstrating the successful encapsulation of ICG and R848 in the PLGA core.
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A growing number of low-risk or intermediate-risk PCa 
cases are diagnosed with the advance of screening 
techniques.29 Focal therapy may play an increasingly 
important role in PCa treatment for its efficient removal of 
prostate cancer lesions without damaging healthy tissues and 
nearby organs.16 In recent years, PTT activated by NIR light is 
Figure 2 PLGA-ICG-R848 NPs plus laser irradiation inhibited PCa cell viability. (A) ICG fluorescence was observed in RM9 cells after 2 h treatment, and stronger fluorescence was 
observed with the longer incubation time in groups of PLGA-ICG and PLGA-ICG-R848. (B) Mean fluorescence intensity (MFI) of ICG fluorescence was quantified in groups of PLGA- 
ICG and PLGA-ICG-R848. (***P < 0.001, n = 10). (C) After RM9 cells were treated with PLGA-ICG-R848 containing different ICG concentrations, the cell viability exhibited no 
significant difference in the group of PLGA-ICG-R848 without laser irradiation. But the viability rate significantly decreased in a dose-dependent manner in the group of PLGA-ICG-R848 
+laser. (*P < 0.05, n = 6). (D) After 4 h treatment, prostate cancer cells of RM9, PC-3, LNCaP and DU-145 were irradiated without or with 808 nm laser. The cell viability of PLGA-ICG 
+laser and PLGA-ICG-R848+laser was significantly inhibited, but there was no significant inhibition in groups of PBS, PBS+laser, PLGA+laser and PLGA-R848+laser (*P < 0.05, n = 5).
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preferred for cancer therapy due to such advantages as easy 
operation, accurate positioning, noninvasive penetrating tissue 
to a certain depth and low toxicity.30 The FDA-approved NIR 
cyanine dye, ICG, can not only cause singlet oxygen genera-
tion for PDT, but also convert absorbed light energy into heat 
for PTT.31,32 In our study, ICG was encapsulated into PLGA 
NPs to improve ICG stability and enhance PTT against PCa, 
which is mainly discussed here. In the cell viability assay, we 
found PLGA-ICG and PLGA-ICG-R848 under laser irradia-
tion significantly inhibited the cell viability of RM9 cells and 
human prostate cancer cell lines, but the NIR light itself caused 
no cytotoxic effect in the absence of photosensitizers including 
ICG. Accumulating evidence indicates that a temperature of 
over 43°C caused by PTT can exert an irreversible damage to 
cancer cells.33,34 During laser irradiation, the subcutaneous 
temperatures in the groups of PLGA-ICG+laser and PLGA- 
ICG-R848+laser were controlled around 50°C, which could 
irreversibly damage PCa cells. Moreover, the groups of 
PLGA-ICG+laser and PLGA-ICG-R848+laser had lower 
luminescent signals of RM9-Luc cells than the control groups, 
revealing the ICG-induced PTT to kill PCa cells. We also 
detected the residual ICG under IVIS-200 Imaging System at 
one week and two weeks after treatment with PLGA-ICG- 
R848 NPs plus laser irradiation (data not shown), indicating 
the sustained release of ICG as well as R848, and a second 
treatment with laser irradiation for better efficacy.
Although focal therapy is an attractive option for well- 
selected patients, it should be noted that both uncertain early 
recurrence risk and a lack of long-term clinical outcome pose 
obstacles to its routine use recommended by most urologic 
associations.7 Therefore, close monitoring after focal therapy 
and its combination with systemic therapy are required to 
ensure a reduced risk of recurrence and the enhanced anti- 
PCa effects. However, there are still few reports studying the 
synergistic effects of focal therapy combined with immu-
notherapy against PCa. Previous studies have reported that 
NIR PTT-based in situ vaccination has the potential to 
enhance immune response and immunological memory 
against tumor recurrence and metastasis with lower toxicity 
but less expensive, less ethic and safety concerns than con-
ventional cancer vaccines, even for such immunologically 
cold tumors as breast cancer.35–38 Similarly, intratumoral 
injection of PLGA-ICG-R848 followed by 808 nm laser 
ablation promoted the release of TAAs in situ to trigger 
specific immune response against PCa and the release of 
R848 as an immunopotentiator to enhance the immune 
response of in situ vaccination and produce longer-lasting 
immunity. Chen et al reported that PLGA NPs co-loaded 
with ICG and imiquimod (R837, TLR7 agonist) using o/w 
single-emulsion method contribute to an elevated secretion of 
such pro-inflammatory cytokines as interleukin-6 (IL-6), 
tumor necrosis factor alpha (TNF-α) and interleukin-12p70 
(IL-12p70) by mature DCs in mice bearing either 4T1 or 
CT26 tumors.37 The immune adjuvant R848 used in our 
study has been reported to enhance antitumor immunity in 
multiple cancers by the differentiation of myeloid-derived 
suppressor cells (MDSCs) into M1-like macrophages,39 the 
polarization of macrophages,40 the maturation of DCs,41 and 
the elevated secretion of pro-inflammatory cytokines. 
Interestingly, according to the recent findings by Kim et al, 
mature DCs stimulated by TLR7/8-agonist-loaded NPs 
increase the secretion of pro-inflammatory cytokines and 
the expression of costimulatory molecules, both of which 
can promote splenic NK cell activation.42 There was no 
significant difference in promoting BMDCs maturation 
between free R848 and PLGA-ICG-R848 NPs. For PLGA- 
ICG-R848 NPs, the release of R848 at 48 h was demon-
strated to cause a similar result of BMDCs maturation com-
pared with free R848. However, compared with free R848, 
R848 encapsulated in PLGA NPs has been proven to aug-
ment the immune response and exhibit strong local immune 
activation without inducing systemic cytokine release and 
immune tolerance.13,43 Correspondingly, PLGA-ICG-R848 
NPs treatment was found to increase the maturation markers 
of BMDCs and contribute to an elevated ratio of splenic NK 
cells in mice bearing RM9-Luc tumor (Figure 5B). NK cells 
may kill RM9 PCa cells through the release of such cytotoxic 
molecules as perforin and granzyme, and the secretion of 
cytokines such as interferon-gamma (IFN-γ) to promote the 
differentiation of T helper type 1 (Th1) cells.44,45 Compared 
with a single injection of R848, cycles of repeated injections 
were developed to circumvent immune tolerance and 
improve the efficacy of cancer immunotherapy.46 To avoid 
repeated injections, R848 encapsulated in NPs can slowly 
release, and subsequently reduce potential adverse events and 
safety risks initiated by cytokine storm.40–42 To date, 
although a growing number of R848 preclinical and clinical 
trials have been performed to verify its efficacy on multiple 
cancers, there are a lack of studies about PCa treatment. 
Recently, Islam et al demonstrated that mRNA vaccine 
pulsed with R848 adjuvant exhibits the anti-tumor efficacy 
in syngeneic mouse models of prostate cancer.47 Our data 
prove that PLGA-ICG-R848 induced the significant matura-
tion of BMDCs, and its combination with laser ablation 
increased the proportion of splenic NK cells, which may 
further contribute to a stronger anticancer efficacy against 
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Figure 3 PLGA-ICG-R848 increases the maturation markers of BMDCs. (A and B) On day 8, the BMDCs were collected and then treated with (1) PBS, (2) PLGA, (3) 
PLGA-ICG, (4) PLGA-R848, (5) PLGA-ICG-R848, (6) R848 (5 μg/mL) and (7) LPS (0.1 μg/mL). After 48h treatment, flow cytometry was performed to analyze the 
percentage of CD11c+CD86+ cells and CD11c+CD80+ cells. (C) The percentage of CD11c+CD86+ cells in any group of PLGA-R848, PLGA-ICG-R848 and R848 (5μg/mL) 
was significantly higher than that in any group of Control, PLGA and PLGA-ICG, and it was the same as CD11c+CD80+ cells (*P < 0.05, n = 3). Data are expressed as the 
mean ± SD from three independent experiments.
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PCa. Further studies to evaluate the anti-metastasis effect and 
long-term maintenance of immunological memory against 
PCa are also required to better understand the therapeutic 
potential of PLGA-ICG-R848 NPs with NIR laser.
This is the first report to assess the antineoplastic 
effect of PLGA-ICG-R848 NPs with NIR laser on 
a mouse subcutaneous PCa model. However, this 
model could not well mimic the cancer cells growing 
Figure 4 Anti-tumor effect of PLGA-ICG-R848 NPs plus NIR laser in vivo. (A and B) During laser irradiation, the subcutaneous temperatures in groups of PBS+laser and 
PLGA-ICG-R848+laser were monitored at 2 min, 4 min, 6 min, 8 min and 10 min by FLIR thermal imager. (C) Two weeks after photothermal therapy, in vivo 
bioluminescence imaging was performed to monitor tumor growth and (D) bioluminescent images were quantified (*P < 0.05, n = 3). (E and F) Spleens were collected 
after two-week treatment and flow cytometry was used to detect the proportion of NK cells in splenocytes (*P < 0.05, n = 3).
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in their natural location, so the orthotopic mouse model 
of PCa should be introduced for future research. 
Meanwhile, multiparametric magnetic resonance ima-
ging (mpMRI) can provide anatomical, functional, and 
physiological parameters of prostate diseases,48 which 
will be of great help to real-time localization and intra-
tumoral injection of PLGA-ICG-R848 NPs when com-
bining PTT with immunotherapy against PCa.49
Conclusion
Here we reported a dual-functional PLGA-ICG-R848 NPs 
which combined PTT with immunotherapy against PCa. 
PLGA-ICG-R848 NPs under NIR laser irradiation signifi-
cantly inhibited the growth of human and mouse prostate 
cancer cell lines. Furthermore, PLGA-ICG-R848 NPs could 
significantly increase the maturation markers of BMDCs. In 
the subcutaneous xenograft model of mouse PCa cell line, 
both the anti-tumor effect and immune response were 
enhanced by PLGA-ICG-R848 NPs-based laser irradiation. 
To sum up, the dual-functional PLGA-ICG-R848 NPs under 
NIR laser irradiation exhibit the anti-tumor efficacy for PCa 
treatment in vitro and in vivo. Therefore, these findings 
could have significant implications in the development of 
therapeutic strategies against low- or intermediate-risk PCa 
by combining PTT with immunotherapy.
Figure 5 The mechanism of anti-tumor efficacy induced by PLGA-ICG-R848 NPs plus NIR laser. (A) The preparation of PLGA-ICG-R848 NPs and their application in vivo. 
(B) Schematic illustration of PLGA-ICG-R848 NPs for PTT and anti-tumor immune response against PCa. 
Abbreviations: NK cells, natural killer cells; mDCs, mature dendritic cells; imDCs, immature dendritic cells.
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necrosis factor alpha; IL-12p70, interleukin-12p70; 
MDSCs, myeloid-derived suppressor cells; IFN-γ, inter-
feron-gamma; Th1 cells, T helper type 1 cells; mpMRI, 
multiparametric magnetic resonance imaging; mDCs, 
mature dendritic cells; imDCs, immature dendritic cells.
Acknowledgments
This research was funded by the Ministry of Education, 
Culture, Sports, Science and Technology of Japan (grant No. 
17K11138), Kobayashi Foundation, and the China Scholarship 
Council. We thank Xianwen Tan, Hideo Ueki and Shunai Li at 
Okayama University for their technical guidance. Wenfeng Lin 
and Chaoming Li are co-first authors for this study.
Disclosure
Prof. Dr. Yasutomo Nasu reports a licensed patent for 
REIC gene. The authors report no other conflicts of inter-
est in this work.
References
1. Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10 
(2):63–89. doi:10.14740/wjon1191
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer 
J Clin. 2020;70(1):7–30. doi:10.3322/caac.21590
3. Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO- 
ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: 
screening, diagnosis, and local treatment with curative intent. Eur 
Urol. 2020.
4. Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO 
-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treat-
ment of relapsing and metastatic prostate cancer. Eur Urol. 2020.
5. Xu J, Qiu Y. Current opinion and mechanistic interpretation of 
combination therapy for castration-resistant prostate cancer. Asian 
J Androl. 2019;21(3):270–278. doi:10.4103/aja.aja_10_19
6. Boettcher AN, Usman A, Morgans A, VanderWeele DJ, 
Sosman J, Wu JD. Past, current, and future of immunotherapies 
for prostate cancer. Front Oncol. 2019;9:884. doi:10.3389/ 
fonc.2019.00884
7. Ahdoot M, Lebastchi AH, Turkbey B, Wood B, Pinto PA. Contemporary 
treatments in prostate cancer focal therapy. Curr Opin Oncol. 2019;31 
(3):200–206. doi:10.1097/CCO.0000000000000515
8. Vitkin N, Nersesian S, Siemens DR, Koti M. The tumor immune 
contexture of prostate cancer. Front Immunol. 2019;10:603. 
doi:10.3389/fimmu.2019.00603
9. Pan C, Liu H, Robins E, et al. Next-generation immuno-oncology 
agents: current momentum shifts in cancer immunotherapy. 
J Hematol Oncol. 2020;13(1):29. doi:10.1186/s13045-020-00862-w
10. Bouzid R, Peppelenbosch M, Buschow SI. Opportunities for conven-
tional and in situ cancer vaccine strategies and combination with 
immunotherapy for gastrointestinal cancers, a review. Cancers 
(Basel). 2020;12(5):1121. doi:10.3390/cancers12051121
11. Hammerich L, Bhardwaj N, Kohrt HE, Brody JD. In situ vaccination 
for the treatment of cancer. Immunotherapy. 2016;8(3):315–330. 
doi:10.2217/imt.15.120
12. Kieffer ME, Patel AM, Hollingsworth SA, Seganish WM. Small 
molecule agonists of toll-like receptors 7 and 8: a patent review 
2014–2020. Expert Opin Ther Pat. 2020;30(11):825–845. 
doi:10.1080/13543776.2020.1825687
13. Ilyinskii PO, Roy CJ, O’Neil CP, et al. Adjuvant-carrying synthetic 
vaccine particles augment the immune response to encapsulated 
antigen and exhibit strong local immune activation without inducing 
systemic cytokine release. Vaccine. 2014;32(24):2882–2895. 
doi:10.1016/j.vaccine.2014.02.027
14. Pesapane F, Patella F, Fumarola EM, et al. The prostate cancer focal 
therapy. Gland Surg. 2018;7(2):89–102. doi:10.21037/gs.2017.11.08
15. Catalona WJ. Prostate cancer screening. Med Clin North Am. 
2018;102(2):199–214. doi:10.1016/j.mcna.2017.11.001
16. Lepor H, Gold S, Wysock J. Focal ablation of prostate cancer. Rev 
Urol. 2018;20(4):145–157. doi:10.3909/riu0809
17. Reinhart MB, Huntington CR, Blair LJ, Heniford BT, 
Augenstein VA. Indocyanine green: historical context, current appli-
cations, and future considerations. Surg Innov. 2016;23(2):166–175. 
doi:10.1177/1553350615604053
18. Wang H, Li X, Tse BW, et al. Indocyanine green-incorporating 
nanoparticles for cancer theranostics. Theranostics. 2018;8 
(5):1227–1242. doi:10.7150/thno.22872
19. Essa D, Kondiah PPD, Choonara YE, Pillay V. The design of poly 
(lactide-co-glycolide) nanocarriers for medical applications. Front 
Bioeng Biotechnol. 2020;8:48. doi:10.3389/fbioe.2020.00048
20. Kim YS, Park JS, Park M, et al. PLGA nanoparticles with multiple 
modes are a biologically safe nanocarrier for mammalian develop-
ment and their offspring. Biomaterials. 2018;183:43–53. doi:10.1016/ 
j.biomaterials.2018.08.042
21. Iqbal M, Zafar N, Fessi H, Elaissari A. Double emulsion solvent 
evaporation techniques used for drug encapsulation. Int J Pharm. 
2015;496(2):173–190. doi:10.1016/j.ijpharm.2015.10.057
22. Xu N, Huang L, Li X, et al. The novel combination of nitroxoline and 
PD-1 blockade, exerts a potent antitumor effect in a mouse model of 
prostate cancer. Int J Biol Sci. 2019;15(5):919–928. doi:10.7150/ 
ijbs.32259
23. Xu P, Xu N, Guo K, et al. Real-time monitoring of tumor progres-
sion and drug responses in a preclinical mouse model of prostate 
cancer. Oncotarget. 2016;7(22):33025–33034. doi:10.18632/ 
oncotarget.8846
submit your manuscript | www.dovepress.com                                                                                                                                                                                                                    
DovePress                                                                                                                                       
International Journal of Nanomedicine 2021:16 2786




































































Powered by TCPDF (www.tcpdf.org)
24. Ashrafizadeh M, Hushmandi K, Rahmani Moghadam E, et al. 
Progress in delivery of siRNA-based therapeutics employing 
nano-vehicles for treatment of prostate cancer. Bioengineering. 
2020;7(3). doi:10.3390/bioengineering7030091.
25. Ashrafizadeh M, Zarrabi A, Hushmandi K, et al. Progress in natural 
compounds/siRNA co-delivery employing nanovehicles for cancer 
therapy. ACS Comb Sci. 2020;22(12):669–700. doi:10.1021/ 
acscombsci.0c00099
26. Zhang J, Wang L, You X, Xian T, Wu J, Pang J. Nanoparticle therapy 
for prostate cancer: overview and perspectives. Curr Top Med Chem. 
2019;19(1):57–73. doi:10.2174/1568026619666190125145836
27. Foroozandeh P, Aziz AA. Insight into cellular uptake and intracellu-
lar trafficking of nanoparticles. Nanoscale Res Lett. 2018;13(1):339. 
doi:10.1186/s11671-018-2728-6
28. Murugan K, Choonara YE, Kumar P, Bijukumar D, Du Toit LC, 
Pillay V. Parameters and characteristics governing cellular internali-
zation and trans-barrier trafficking of nanostructures. 
Int J Nanomedicine. 2015;10:2191–2206. doi:10.2147/IJN.S75615
29. Klotz L. Contemporary approach to active surveillance for favorable risk 
prostate cancer. Asian J Urol. 2019;6(2):146–152. doi:10.1016/j. 
ajur.2018.12.003
30. Liu B, Li C, Cheng Z, Hou Z, Huang S, Lin J. Functional nanoma-
terials for near-infrared-triggered cancer therapy. Biomater Sci. 
2016;4(6):890–909. doi:10.1039/C6BM00076B
31. Zhou Y, Liu S, Hu C, Cai L, Pang M. A covalent organic framework 
as a nanocarrier for synergistic phototherapy and immunotherapy. 
J Mater Chem B. 2020;8(25):5451–5459. doi:10.1039/D0TB00679C
32. Xu P, Liang F. Nanomaterial-based tumor photothermal immunotherapy. 
Int J Nanomedicine. 2020;15:9159–9180. doi:10.2147/IJN.S249252
33. Nomura S, Morimoto Y, Tsujimoto H, et al. Highly reliable, targeted 
photothermal cancer therapy combined with thermal dosimetry using 
a near-infrared absorbent. Sci Rep. 2020;10(1):9765. doi:10.1038/ 
s41598-020-66646-x
34. Zheng M, Yue C, Ma Y, et al. Single-step assembly of DOX/ICG 
loaded lipid–polymer nanoparticles for highly effective chemo- 
photothermal combination therapy. ACS Nano. 2013;7 
(3):2056–2067. doi:10.1021/nn400334y
35. Zou L, Wang H, He B, et al. Current approaches of photothermal 
therapy in treating cancer metastasis with nanotherapeutics. 
Theranostics. 2016;6(6):762–772. doi:10.7150/thno.14988
36. Xu X, Lu H, Lee R. Near infrared light triggered photo/immuno-ther-
apy toward cancers. Front Bioeng Biotechnol. 2020;8:488. 
doi:10.3389/fbioe.2020.00488
37. Chen Q, Xu L, Liang C, Wang C, Peng R, Liu Z. Photothermal 
therapy with immune-adjuvant nanoparticles together with check-
point blockade for effective cancer immunotherapy. Nat Commun. 
2016;7(1):13193. doi:10.1038/ncomms13193
38. Sadeghi I, Byrne J, Shakur R, Langer R. Engineered drug delivery 
devices to address global health challenges. J Control Release. 
2021;331:503–514. doi:10.1016/j.jconrel.2021.01.035
39. Liu Z, Xie Y, Xiong Y, et al. TLR 7/8 agonist reverses oxaliplatin 
resistance in colorectal cancer via directing the myeloid-derived 
suppressor cells to tumoricidal M1-macrophages. Cancer Lett. 
2020;469:173–185. doi:10.1016/j.canlet.2019.10.020
40. Rodell CB, Arlauckas SP, Cuccarese MF, et al. TLR7/8-agonist- 
loaded nanoparticles promote the polarization of tumour-associated 
macrophages to enhance cancer immunotherapy. Nat Biomed Eng. 
2018;2(8):578–588. doi:10.1038/s41551-018-0236-8
41. Chen PM, Pan WY, Wu CY, et al. Modulation of tumor microenvir-
onment using a TLR-7/8 agonist-loaded nanoparticle system that 
exerts low-temperature hyperthermia and immunotherapy for in situ 
cancer vaccination. Biomaterials. 2020;230:119629. doi:10.1016/j. 
biomaterials.2019.119629
42. Kim H, Khanna V, Kucaba TA, et al. TLR7/8 agonist-loaded nano-
particles augment NK cell-mediated antibody-based cancer 
immunotherapy. Mol Pharm. 2020;17(6):2109–2124. doi:10.1021/ 
acs.molpharmaceut.0c00271
43. Kim H, Griffith TS, Panyam J. Poly(d,l-lactide-co-glycolide) nanoparti-
cles as delivery platforms for TLR7/8 agonist-based cancer vaccine. 
J Pharmacol Exp Ther. 2019;370(3):715–724. doi:10.1124/ 
jpet.118.254953
44. Ferlazzo G, Morandi B. Cross-talks between natural killer cells and 
distinct subsets of dendritic cells. Front Immunol. 2014;5:159. 
doi:10.3389/fimmu.2014.00159
45. Bottcher JP, Bonavita E, Chakravarty P, et al. NK cells stimulate 
recruitment of cDC1 into the tumor microenvironment promoting 
cancer immune control. Cell. 2018;172(5):1022–1037e1014. 
doi:10.1016/j.cell.2018.01.004
46. Michaelis KA, Norgard MA, Levasseur PR, et al. Persistent toll-like 
receptor 7 stimulation induces behavioral and molecular innate 
immune tolerance. Brain Behav Immun. 2019;82:338–353. 
doi:10.1016/j.bbi.2019.09.004
47. Islam MA, Rice J, Reesor E, et al. Adjuvant-pulsed mRNA vaccine 
nanoparticle for immunoprophylactic and therapeutic tumor suppres-
sion in mice. Biomaterials. 2021;266:120431. doi:10.1016/j. 
biomaterials.2020.120431
48. Girometti R, Cereser L, Bonato F, Zuiani C. Evolution of prostate 
MRI: from multiparametric standard to less-is-better and different-is 
better strategies. Eur Radiol Exp. 2019;3(1):5. doi:10.1186/s41747- 
019-0088-3
49. Connor MJ, Gorin MA, Ahmed HU, Nigam R. Focal therapy for 
localized prostate cancer in the era of routine multi-parametric MRI. 
Prostate Cancer Prostatic Dis. 2020;23(2):232–243. doi:10.1038/ 
s41391-020-0206-6
International Journal of Nanomedicine                                                                                             Dovepress 
Publish your work in this journal 
The International Journal of Nanomedicine is an international, peer- 
reviewed journal focusing on the application of nanotechnology in 
diagnostics, therapeutics, and drug delivery systems throughout the 
biomedical field. This journal is indexed on PubMed Central, 
MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine,  
Journal Citation Reports/Science Edition, EMBase, Scopus and the 
Elsevier Bibliographic databases. The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.  
Submit your manuscript here: https://www.dovepress.com/international-journal-of-nanomedicine-journal
International Journal of Nanomedicine 2021:16                                                                          submit your manuscript | www.dovepress.com                                                                                                                                                                                                                       
DovePress                                                                                                                       
2787




































































Powered by TCPDF (www.tcpdf.org)
